Blueprint inks deal to buy lung cancer biotech LengoTargeted cancer drug specialist Blueprint Medicines has agreed to pay $250 million upfront to acquire Lengo Therapeutics and Share XBlueprint inks deal to buy lung cancer biotech Lengohttps://pharmaphorum.com/news/blueprint-inks-deal-to-buy-lung-cancer-biotech-lengo/
FDA clears Takeda drug for post-transplant CMV infectionsTakeda has scored the first-ever FDA approval of a treatment for refractory cytomegalovirus (CMV) infections in organ transplant Share XFDA clears Takeda drug for post-transplant CMV infectionshttps://pharmaphorum.com/news/fda-clears-takeda-drug-for-post-transplant-cmv-infections/
Takeda buys GammaDelta to boost cancer cell therapy credentialsJapanese drugmaker Takeda has said it will exercise its option to buy UK-based GammaDelta Therapeutics, a specialist in Share XTakeda buys GammaDelta to boost cancer cell therapy credentialshttps://pharmaphorum.com/news/takeda-buys-gammadelta-to-boost-cancer-cell-therapy-credentials/
FDA panel backs Takeda’s CMV drug for transplant patientsTakeda is closing on a first FDA approval in the treatment of refractory cytomegalovirus (CMV) infections in organ Share XFDA panel backs Takeda’s CMV drug for transplant patientshttps://pharmaphorum.com/news/fda-panel-backs-takedas-cmv-drug-for-transplant-patients/
Takeda halts trial of orexin drug in narcolepsy on safety groundsJapanese drugmaker Takeda has suspended dosing in phase 2 trials of its orexin agonist TAK-994, saying it had Share XTakeda halts trial of orexin drug in narcolepsy on safety groundshttps://pharmaphorum.com/news/takeda-halts-trial-of-orexin-drug-in-narcolepsy-on-safety-grounds/
Takeda bags Japanese approval for Crohn’s cell therapy AlofiselTakeda has chalked up another milestone for its Alofisel cell therapy for a complication of Crohn’s disease, becoming Share XTakeda bags Japanese approval for Crohn’s cell therapy Alofiselhttps://pharmaphorum.com/news/takeda-bags-japanese-approval-for-crohns-cell-therapy-alofisel/
Takeda gets a win for its Wave1 pipeline, as Exkivity nabs FDA approvalTakeda has had a run of bad luck with its Wave1 pipeline of new drug candidates of late, Share XTakeda gets a win for its Wave1 pipeline, as Exkivity nabs FDA approvalhttps://pharmaphorum.com/news/takeda-gets-a-win-for-its-wave1-pipeline-as-exkivity-nabs-fda-approval/
Gamble by Takeda on unproven cancer mechanism draws a blankTakeda says a phase 3 trial of its cancer candidate pevonedistat – a class-leading NEDD8-activating enzyme inhibitor – Share XGamble by Takeda on unproven cancer mechanism draws a blankhttps://pharmaphorum.com/news/takeda-gamble-on-unproven-cancer-mechanism-draws-a-blank/
Takeda spins norovirus vaccine out into separate companyTakeda has decided development of its norovirus vaccine candidate outside Japan will be more efficient if it is Share XTakeda spins norovirus vaccine out into separate companyhttps://pharmaphorum.com/news/takeda-spins-norovirus-vaccine-out-into-separate-company/
